Cargando…
Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
The efficacy of imatinib in chronic myeloid leukemia has been remarkable, but the development of resistance and the persistence of minimal residual disease have dampened the initial enthusiasm for this much heralded ‘magic bullet’. Much progress has been made in elucidating the mechanisms which unde...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886328/ https://www.ncbi.nlm.nih.gov/pubmed/20616897 |